CD274 and neoplasm: Several biomarkers have been identified to be associated with the sensitivity of ICI therapy, including high programmed death-ligand 1 (PD-L1) expression [2, 6, 7], a high tumor mutational burden (TMB) [6, 7], microsatellite instability-high (MSI-H) [8] and a deficiency in mismatch repair (MMR)[9].